A retrospective analysis of clinical use of alirocumab in lipoprotein apheresis patients

Anne C. Goldberg, Richard L. Dunbar, Linda Hemphill, Stephan P. Babirak, Gerald Wilson, Michael Wooten, Mohamed Iydroose, Kelley Dacus, Heather Minchew, Julie Ann Dutton, Patrick M. Moriarty

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Background: The previously published ODYSSEY ESCAPE trial demonstrated a significant reduction in the use of lipoprotein apheresis for heterozygous familial hypercholesterolemia (HeFH) patients when placed on alirocumab 150 mg every 2 weeks. In patients with HeFH who have consistently elevated levels of low-density lipoprotein cholesterol (LDL-C) despite maximally tolerated statin therapy, current lipid guidelines recommend apheresis. Although apheresis reduces LDL-C levels by 50%–75%, it must be repeated, as frequently as every 1–2 weeks. Objective: To assess clinical experience with apheresis and alirocumab for patients in a real-world practice setting. Methods: This retrospective review included patients from 5 apheresis centers who were treated with apheresis and had started alirocumab therapy. In addition to LDL-C levels, total cholesterol, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, triglycerides, and particle numbers were evaluated if data were available. Results: Eleven of the 25 (44%) patients discontinued apheresis completely after initiation of alirocumab therapy, having achieved LDL-C <70 mg/dL or >50% reduction from baseline levels. Among the 14 patients who remained on apheresis, seven decreased the frequency of apheresis sessions. No significant safety problems were reported. Conclusion: Alirocumab lowered LDL-C levels by an average of 55.5% in patients receiving apheresis for elevated LDL-C. Seventy-two percent of patients on alirocumab therapy discontinued or reduced the frequency of apheresis treatment. However, some patients continued to require apheresis due to elevated lipoprotein(a), extremely elevated LDL-C, or if alirocumab therapy was discontinued due to less than anticipated LDL-C reduction.

Original languageEnglish
Pages (from-to)818-824
Number of pages7
JournalJournal of Clinical Lipidology
Issue number6
StatePublished - Nov 1 2020


  • Alirocumab
  • Apheresis
  • LDL-C
  • PCSK9 inhibitor
  • Retrospective


Dive into the research topics of 'A retrospective analysis of clinical use of alirocumab in lipoprotein apheresis patients'. Together they form a unique fingerprint.

Cite this